Diffuse Large B-cell Lymphoma
8 drugs1,373 FAERS reportsMedDRA PT
GET
/api/v1/reaction/diffuse-large-b-cell-lymphomaReference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.
Drugs reporting Diffuse Large B-cell Lymphoma (8)
Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.
- 1Epcoritamab22920%
- 2Tisagenlecleucel3157.1%
- 3Tafasitamab364.1%
- 4Polatuzumab Vedotin3634.0%
- 5Axicabtagene Ciloleucel3633.9%
- 6Loncastuximab Tesirine102.8%
- 7Mosunetuzumab212.5%
- 8Glofitamab361.8%
Related reactions
Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.
- Diffuse Large B-cell Lymphoma Recurrent5 shared · 0.63
- Hypogammaglobulinaemia3 shared · 0.25
- Cytopenia4 shared · 0.22
- Immune Effector Cell-associated Neurotoxicity Syndrome4 shared · 0.21
- Lymphoma2 shared · 0.20
- Cytokine Release Syndrome7 shared · 0.19
- Blood Lactate Dehydrogenase Increased3 shared · 0.18
- Neurotoxicity2 shared · 0.11
- Neutrophil Count Decreased3 shared · 0.06
- Hypoxia2 shared · 0.04
Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.